Overview

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

Status:
Active, not recruiting

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

The objective of this protocol is to improve survival for adults with acute lymphoblastic leukemia or acute lymphoblastic lymphoma by reducing systemic and central nervous system (CNS) relapse with acceptable toxicity using intensive chemotherapy with liposomal cytarabine (Depocyt®) CNS prophylaxis.

Phase:

Phase 2

Details

Lead Sponsor:

University of California, San Diego

Collaborators:

Leadiant Biosciences, Inc.
Sigma Tau Pharmaceuticals, Inc.

Treatments:

Asparaginase
Cortisol succinate
Cyclophosphamide
Cytarabine
Dasatinib
Daunorubicin
Etoposide
Etoposide phosphate
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Leucovorin
Methotrexate
Pegaspargase
Prednisone
Rituximab
Vincristine